Cristina Raimondi

Cristina Raimondi

Auto-generated profile, based on publicly available information

Cristina Raimondi

Dipartimento di Medicina Molecolare, Sapienza Università di Roma, Rome, Italy.

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2017 in OncoImmunology
Verified
Journal Article
Closed access
CRCristina Raimondi
Cristina Raimondi
GCGuido Carpino
Guido Carpino
CNChiara Nicolazzo
Chiara Nicolazzo
AGAngela Gradilone
Angela Gradilone
WGWalter Gianni
Walter Gianni
PGPaola Gazzaniga
Paola Gazzaniga
The programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) pathway has emerged as a critical inhibitory pathway regulating T-cell response in non-small-cell lung cancer (NSCLC), and the development of PD-1/PD-L1 inhibitors has changed the landscape of NSCLC therapy. Nevertheless, the high degree of non-responders demonstrates that we are still far from completely understanding the events underlying tumor immune resistance. Although the expression of PD-L1 in tumor tissue has been correlated with clinical response to anti PD-1 inhibitors, the ability of this marker to discriminate the subgroup of patients who derive benefit from immunotherapy is suboptimal. Circulating tumor cells (CTCs), as an accessible source of tumor for biologic characterization that can be serially obtained with minimally invasive procedure, hold significant promise to facilitate treatment-specific biomarkers discovery. We recently demonstrated that the presence of PD-L1 on CTCs apparently predicts resistance to the anti-PD-1 Nivolumab in metastatic NSCLC patients and that PD-L1 positive CTCs usually have an elongated morphology that can be ascribed to epithelial–mesenchymal transition (EMT). We here demonstrate for the first time that PD-L1 positive CTCs isolated from NSCLC patients are characterized by partial EMT phenotype, and hypothesize that the co-expression of PD-L1 and EMT markers might represent for these cells a possible molecular background for immune escape.

1 December 2011
Verified
Journal Article
Closed access
AGAngela Gradilone
Angela Gradilone
RIRoberto Iacovelli
Roberto Iacovelli
ECEnrico Cortesi
Enrico Cortesi
CRCristina Raimondi
Cristina Raimondi
WGWalter Gianni
Walter Gianni
PGPaola Gazzaniga
Paola Gazzaniga

10 April 2014 in Expert Review of Molecular Diagnostics
Verified
Journal Article
Closed access
CRCristina Raimondi
Cristina Raimondi
AGAngela Gradilone
Angela Gradilone
PGPaola Gazzaniga
Paola Gazzaniga
Although several studies have demonstrated the prognostic and predictive potential of circulating tumor cells (CTCs), to date their evaluation still has not impacted the treatment strategy. There is wide consensus that CTC assessment would be more beneficial in early stage cancer, especially in those tumor types characterized by early progression and a lack of prognostic markers. Non-muscle-invasive bladder cancer represents an optimal model to this purpose. In fact, the rate of metastatic spread ranges between 20 and 40%, which is unacceptable for a 'superficial' tumor and unexpected in an early stage cancer. This may be due to the presence of non-clinically detectable micrometastases. CTCs may be used as a noninvasive, real-time tool for the stratification of early stage bladder cancer patients according to individual risk of progression.

22 November 2018
Verified
Book Chapter
Closed access
PDF file
CNChiara Nicolazzo
Chiara Nicolazzo
AGAngela Gradilone
Angela Gradilone
GCGuido Carpino
Guido Carpino
PGPaola Gazzaniga
Paola Gazzaniga
CRCristina Raimondi
Cristina Raimondi

1 August 2010 in Current Cancer Drug Targets
Verified
Journal Article
Closed access
PDF file
CRC. Raimondi
C. Raimondi
GNG. Naso
G. Naso
AGA. Gradilone
A. Gradilone
WGW. Gianni
W. Gianni
ECE. Cortesi
E. Cortesi
PGP. Gazzaniga
P. Gazzaniga
Abstract: What clinical oncologists learned about the metastatic process, is that it is the main cause of cancer-related deaths. What scientists learned about the metastatic disease, is that it is due to a highly selective process, which involves a minority of tumor cells that are able to survive within the bloodstream, and to initiate a new growth in distant sites. These cells “in transit” are known as circulating tumor cells (CTCs). Although their nature is not fully understood, what is widely accepted, is that they are drug resistant, and that their presence may represent the main reason for treatment failure. Despite this body of evidence, the pharmacological approach against cancer, with both chemotherapic and biological drugs, is still targeted on the primary tumor, raising the question as to whether we are missing the target. Targeting circulating tumor cells, may represent a new promising approach to individualize anticancer therapy.

Verified
Journal Article
Open access
PDF file
Chiara NicolazzoChiara Nicolazzo
Chiara Nicolazzo
CRCristina Raimondi
Cristina Raimondi
FLFlavia Loreni
Flavia Loreni
PGPaola Gazzaniga
Paola Gazzaniga
AGAngela Gradilone
Angela Gradilone
To the Editor, We read with great interest the article “Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy” published by Coco, S. et al. in International Journal of Molecular Sciences on 11 May 2017 [1].